The composition of plasma, unlike clotting factor concentrates, is extremely complex and, between 19, Bernard Horowitz implemented a modified S/D method adapted to its higher lipid content and able to ensure an effective virucidal power. Since then it has become the most widely spread industrial method for the virucidal treatment of plasma-derived medicinal products. However, the S/D method of pathogen inactivation was patented in 1985 for the treatment of concentrates of coagulation factors. Solvent detergent pathogen inactivation of fresh frozen plasmaĪ study conducted in the early seventies with tri-nitrobutylphosphate (TNBP) solvent substantiated its effectiveness in the disruption of lipid-enveloped viruses. The pharmaceutical characteristics of S/D plasma and the clinical experience on its use will be the focus of this narrative review. Although many millions of therapeutic doses of S/D inactivated products have been used to date, there is no report on transmission of viral infections caused by enveloped viruses in recipients. On the contrary, the S/D method does not have any effect on non-enveloped viruses.Ĭurrently, S/D treatment for pathogen reduction of plasma for transfusion and plasma-derived medicinal products is the most common, validated and robust industrial method for the virucidal treatment of blood products. Actually, this technique turned out to be a tool capable of damaging the membrane of lipid-enveloped viruses, cells and the majority of protozoa without harming the labile coagulation factors V and VIII. The solvent/detergent (S/D) pathogen inactivation method was developed in the early eighties for the inactivation of enveloped viruses in plasma-derived medicinal products.

Demo on effects of solvents